Can The Medicines Company Rebound From A Phase III Blow?

Antithrombotic cangrelor fails against Plavix in angioplasty, but the company says the drug’s profile lends to an indication as a bridge therapy for surgery patients who can’t stay on clopidogrel.

More from Archive

More from Pink Sheet